AMERICAN MEDICAL SYSTEMS LOGO American Medical Systems, Inc. logo. (PRNewsFoto)[AG] MINNEAPOLIS, MN USA

    MINNEAPOLIS, June 27 /PRNewswire/ --
    American Medical Systems Holdings, Inc. (Nasdaq: AMMD) announced today
that it has priced its follow-on public offering of 7,000,000 shares of common
stock at $16.40 per share.  Of the 7,000,000 shares, 3,500,000 shares are
being issued and sold by American Medical Systems and 3,500,000 shares are
being sold by a selling stockholder, Warburg, Pincus Equity Partners, L.P.
Warburg, Pincus has also granted the underwriters an option to purchase up to
an additional 1,050,000 shares to cover over-allotments, if any.
    (Photo:  http://www.newscom.com/cgi-bin/prnh/20000710/AMSLOGO )
    The offering is being managed by U.S. Bancorp Piper Jaffray and co-managed
by Banc of America Securities LLC, J.P. Morgan Securities Inc. and Robertson
Stephens, Inc.
    The net proceeds to the Company from the offering will be approximately
$53.6 million.  American Medical Systems plans to use the proceeds from the
offering to repay debt and for general corporate purposes, including to fund
future product development and acquisitions of technologies, products and
companies.
    American Medical Systems, headquartered in Minneapolis, is a medical
technology company with 500 employees worldwide.  American Medical Systems
products include a large portfolio of devices to treat both male and female
incontinence, devices for the diagnosis and treatment of erectile dysfunction,
devices for urethral obstruction caused by benign prostatic hyperplasia (BPH)
(enlarged prostate disease) and advanced surgical products used in
transurethral resection of the prostate.
    To request a copy of the final prospectus for the offering, you should
write to U.S. Bancorp Piper Jaffray Equity Capital Markets, 800 Nicollet Mall,
Suite 800, Minneapolis, Minnesota  55402-7020.
    Forward-looking statements contained in this press release are made under
the Safe Harbor Provision of the Private Securities Litigation Reform Act of
1995.  Any such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those anticipated.  Such
factors are described in the Company's final prospectus and other documents
filed with the Securities and Exchange Commission.

Link to this page: